Working… Menu

Pembrolizumab as Neoadjuvant Treatment in HCC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03337841
Recruitment Status : Unknown
Verified November 2017 by Masatoshi Kudo, Kindai University.
Recruitment status was:  Not yet recruiting
First Posted : November 9, 2017
Last Update Posted : November 9, 2017
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Masatoshi Kudo, Kindai University

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : October 31, 2019
Estimated Study Completion Date : October 31, 2020